NuPulseCV
Raleigh, US · Founded 2010 · Delaware corporation · 1 known investors
Find your way into NuPulseCV
NuPulseCV develops the Voyage device, a cardiac support technology aimed at patients with heart failure who are treated at both major institutions and community hospitals. The company is guided by a scientific advisory board of clinically active cardiologists and cardiac surgeons.
Founders & leadership
NuPulseCV was founded in 2010 by VALLUVAN JEEVANANDAM.
VJ
VALLUVAN JEEVANANDAMFounder
GS
GREG SCOTTNamed on SEC filing
RS
RICHARD SHERMANNamed on SEC filing
AS
ALEX SHLYANKEVICHNamed on SEC filing
SP
SONNA PATEL-RAMANNamed on SEC filing
DA
DOUGLAS ALTSCHULERNamed on SEC filing
BN
BRIAN NOVAKNamed on SEC filing
Board
BN
BRIAN NOVACKBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$14.2M disclosed across 3 rounds · 2014–2020
▶$2.1MraisedMar 2020 · 2 investors · BiotechnologyRule 506(b)
▶$2.1MraisedMar 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas AltschulerExecutive Officer, Director
- Richard ShermanDirector
- Brian NovackDirector
- Alex ShlyankevichDirector
- Greg ScottDirector
- Dirk SimmonsDirector
- Sonna Patel-RamanExecutive Officer
- Offering amount
- $20M
- Amount sold
- $2.1M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedJul 2018 · 13 investors · BiotechnologyRule 506(b)
▶$5.4MraisedJul 2018 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- GREG SCOTTDirector
- RICHARD SHERMANDirector
- ALEX SHLYANKEVICHDirector
- SONNA PATEL-RAMANExecutive Officer
- DOUGLAS ALTSCHULERExecutive Officer, Director
- BRIAN NOVAKDirector
- Offering amount
- $25M
- Amount sold
- $5.4M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.7MraisedAug 2014 · 13 investors · BiotechnologyRule 506(b)
▶$6.7MraisedAug 2014 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- BRIAN NOVACKDirector
- RICHARD SHERMANDirector
- VALLUVAN JEEVANANDAMDirector
- DOUGLAS ALTSCHULERExecutive Officer, Director
- Offering amount
- $6.7M
- Amount sold
- $6.7M
- Minimum investment
- $150K
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $256.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does NuPulseCV do?
- NuPulseCV develops the Voyage device, a cardiac support technology aimed at patients with heart failure who are treated at both major institutions and community hospitals. The company is guided by a scientific advisory board of clinically active cardiologists and cardiac surgeons.
- Who founded NuPulseCV?
- NuPulseCV was founded by VALLUVAN JEEVANANDAM in 2010.
- Who are NuPulseCV's investors?
- NuPulseCV's investors include Broadview Ventures.
- How much funding has NuPulseCV raised?
- NuPulseCV has disclosed $14.2M raised across 3 rounds.
- Where is NuPulseCV headquartered?
- NuPulseCV is headquartered in Raleigh, US.